Beam Therapeutics (MEX:BEAM) Total Liabilities: MXN5,705 Mil (As of Mar. 2026)

What is Beam Therapeutics Total Liabilities?

Beam Therapeutics MEX:BEAM 66 Total Liabilities is MXN5,705 Mil as of Mar. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 66/100 and a GF Value™ of MXN525.92 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Beam Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was MXN5,705 Mil.

Beam Therapeutics's quarterly Total Liabilities declined from Sep. 2025 (MXN6,330.20 Mil) to Dec. 2025 (MXN4,372.13 Mil) but then increased from Dec. 2025 (MXN4,372.13 Mil) to Mar. 2026 (MXN5,704.83 Mil).

Beam Therapeutics's annual Total Liabilities declined from Dec. 2023 (MXN8,120.23 Mil) to Dec. 2024 (MXN7,722.43 Mil) and declined from Dec. 2024 (MXN7,722.43 Mil) to Dec. 2025 (MXN4,372.13 Mil).

Beam Therapeutics Total Liabilities Related Terms

Beam Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Total Liabilities Chart

Beam Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

13,287.23

11,858.25

8,120.23

7,722.43

4,372.13

Beam Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															7,033.20	6,483.72	6,330.20	4,372.13	5,704.83

66GF Score

Beam Therapeutics Inc MEX:BEAM

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Beam Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Beam Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1745.383	+	(2516.459	+	110.284
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	4,372

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	26669.629	-	22297.503
	=	4,372

Beam Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1344.608	+	(4256.457	+	103.76
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	5,705

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	26702.786	-	20997.961
	=	5,705

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of MXN5,705 Mil mean?

Beam Therapeutics (MEX:BEAM) has a Total Liabilities of MXN5,705 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Beam Therapeutics and its competitors.

Is Beam Therapeutics' Total Liabilities too high?

Beam Therapeutics' current Total Liabilities is MXN5,705 Mil. Overall, Beam Therapeutics has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Beam Therapeutics' Total Liabilities compare to ELVN and IDYA?

Beam Therapeutics' Total Liabilities of MXN5,705 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Beam Therapeutics and its competitors. Beam Therapeutics's current Total Liabilities is MXN5,705 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Beam Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN525.92, compared to a current price of MXN628.46 — trading 19.5% above its estimated fair value. The current Total Liabilities is MXN5,705 Mil. Beam Therapeutics' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Total Liabilities is MXN5,705 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN628.46 is trading 19.5% above its estimated GF Value™ of MXN525.92. GuruFocus considers Beam Therapeutics to be Modestly Overvalued.

Key valuation signals for MEX:BEAM:

Total Liabilities: MXN5,705 Mil
GF Value™: MXN525.92 vs. price of MXN628.46 (19.5% above fair value)
GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ELVN IDYA PBLS DYN ARQT ALMS CPRX CRNX NAMS QURE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges BEAM:USA

Address 238 Main Street, Cambridge, MA, USA, 02142

Website https://www.beamtx.com

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

66GF Score

Get the complete analysis for MEX:BEAM

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN628.46

Price

MXN525.92

GF Value

View MEX:BEAM Analysis

See Total Liabilities data for all stocks →